reports
- Sean Conroy
Ondine Biomedical - Steriwave initiates UK pilot study with NHS
Ondine Biomedical has announced the initiation of its first NHS pilot study for Steriwave, the company’s lead product for nasal photodisinfection. The pilot is based at the Mid Yorkshire Teaching NHS Trust and will assess the effectiveness of Ondine’s technology in preventing surgical site infections (SSIs). The study will have a duration of six months and involve 500 hip and knee surgery patients using Steriwave for nasal decolonisation prior to surgery. With hospital-associated infections (HAI...
- Sean Conroy
Ondine Biomedical - Proprietary platform testing standard of care
Ondine Biomedical is focused on becoming a leader in tackling antimicrobial resistance (AMR) at the source, by leveraging its capabilities and proprietary platform technologies. The company specialises in the field of photodisinfection, a unique approach to preventing the spread of infections that uses light to destroy pathogens. Its lead product Steriwave was first approved by Health Canada, and Ondine has since partnered with HCA Healthcare, a leading US hospital group, to run US clinical tria...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.